


FORM PTO-1449 (Modified)	U.S. Dept. of Commerce Patent and Trademark Office	Atty. Docket No.: 1588.005	Serial No.: 09/665,493
INFORMATION DISCLOSURE CITATION		JUN 08 2001 Applicants: William Manning et al.	JUN 12 2001 TECH CENTER 1600/2900
(Use several sheets if necessary)		Filing Date: September 20, 2000 Group: 1646	



U.S. PATENT DOCUMENTS

*Examiner Initial		Document Number	Date	Name	Class	Subclass	Filing Date If Appropriate
TNT	AA	5,792,845	08/11/98	O'Reilly et al.	536	23.1	10/20/94
TNT	AB	5,641,749	06/24/97	Yan et al.	514	12	11/29/95

FOREIGN PATENT DOCUMENTS

		Document Number	Publ. Date	Country	Class	Subclass	Trans- Yes	lation No
TNT	BA	WO 98/13071	04/02/98	PCT	—	—		
	BB	WO 98/51323	11/19/98	PCT	—	—		
	BC	WO 99/16889	04/08/99	PCT	—	—		
	BD	WO 99/45952	09/16/99	PCT	—	—		
	BE	WO 95/26409	10/05/95	PCT	—	—		
	BF	WO 00/01815	01/13/00	PCT	—	—		
	BG	WO 00/15822	03/23/00	PCT	—	—		
	BH	407,122 A1	01/09/91	Europe	—	—		
TNT	BI	JP 11100327	04/13/99	Japan			X (abstract only)	

OTHER CITATIONS (Including Author, Title, Date, Pertinent Pages, Etc.)

TNT	CA	Oikawa et al., "Three Novel Synthetic Retinoids, Re 80, Am 580 and Am 80, all Exhibit Anti-Angiogenic Activity in vivo" <u>European Journal of Pharmacology</u> 249:113-116, 1993
	CB	Luthert and Chong, "Photoreceptor Rescue" <u>Eye</u> 12:591-596, 1998
	CC	Fotsis et al., "The Endogenous Oestrogen Metabolite 2-Methoxyoestradiol Inhibits Angiogenesis and Suppresses Tumour Growth" <u>Nature</u> 368:237-239, March 17, 1994
	CE	Akimoto et al., "Adenovirally Expressed Basic Fibroblast Growth Factor Rescues Photoreceptor Cells in RCS Rats" <u>Investigative Ophthalmology and Visual Science</u> 40(2):273-279, February, 1999
	CF	Peterson et al., "Enhanced Survival of Photoreceptors in p23h Mutant Rhodopsin Transgenic Rats by Adeno-Associated Virus (AAV)-Mediated Delivery of Neurotrophic Genes" <u>IOVS</u> 39:S1117, March 15, 1998
	CG	Shafiee et al., "Thrombospondin Peptides Inhibit Angiogenesis in Retinal Explant Assay and Rat Model of Retinopathy of Prematurity" <u>IOVS</u> 38:S984, 1997
TNT	CH	Smith et al., "Inhibition of Retinal Neovascularization with an IGF-1 Receptor Antagonist" <u>IOVS</u> 39(4):S450, March 15, 1998
		Cayouette and Gravel, "Adenovirus-Mediated Gene Transfer of Ciliary Neurotrophic Factor can Prevent Photoreceptor Degeneration in the Retinal Degeneration (rd) Mouse" <u>Human Gene Therapy</u> 8:423-430, March 1, 1997
Examiner		Date Considered
<i>John</i>	<i>—</i>	2.06.03

\*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Please type a plus sign (+) in this box → 

Approved for use through 10/31/2002. OMB 0651-0031

Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO

Complete if Known

INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet

1

of

Application Number	09/665,493	JUL 15 2002 TECH CENTER 1600/2000
Filing Date	09/20/2000	
First Named Inventor	Manning, Jr.	
Group Art Unit	1632	
Examiner Name	T. Ton	

Attorney Docket Number

20263-40

## FOREIGN PATENT DOCUMENTS

Examiner Initials	Cite No. <sup>1</sup>	Foreign Patent Document			Date of Publications of Cited Documents MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T <sup>6</sup>
		Office <sup>3</sup>	Number <sup>4</sup>	Kind Code <sup>5</sup>				
TNT	AA	WO	99/36511	A2	07-22-1999	Chiron Corporation		
TNT	AB	WO	99/66959	A2	12-29-1999	Selective Genetics, Inc.		
TNT	AC	WO	00/54813	A2	09-21-2000	Chiron Corporation		
TNT	AD	WO	00/71582	A1	11-30-2000	Human Genome Sciences, Inc.		

Examiner Signature		Date Considered	2.06.03
--------------------	---	-----------------	---------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup>Unique citation designation number. <sup>2</sup>See attached Kinds of U.S. Patent Documents. <sup>3</sup>Enter Office that issued the document, by the two-letter code (WIPO Standard ST.). <sup>4</sup>For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent documents. <sup>5</sup>Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup>Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS, SEND TO: Commissioner for Patents, Washington, DC 20231.

OC: 153591 v01 07.01.2002

RECEIVED